Document is current
Any future updates will be listed below
-
Authors
Piva, Vittoria Matilde
De Grandis, Maria Caterina
Zuin, Irene Sole
Angerilli, Valentina
Nappo, Floriana
Alfieri, Rita
Ahcene Djaballah, Selma
Murgioni, Sabina
Bergamo, Francesca
Fassan, Matteo
Valmasoni, Michele
Lonardi, Sara
-
Funding
Funding for this research was provided by:
IOV-IRCCS Grant 2019 “Gastric cancer: prognostic and predictive value of the new target”
- License Information
-
More Information
Article History
Received: 29 March 2022
Accepted: 12 September 2022
First Online: 22 October 2022
Declarations
:
: Sara Lonardi reports personal fees (as speaker bureau or advisor) from Amgen, Merck Serono, Lilly, Astra Zeneca, Incyte, Daiichi-Sankyo, Bristol-Myers Squibb, Servier, MSD, Roche, Pierre-Fabre, GSK, and received research grants from Amgen, Merck Serono, Bayer, Roche, Lilly, Astra Zeneca, Bristol-Myers Squibb, unrelated to the current work. Matteo Fassan reports personal fees (as speaker bureau or advisor) from Roche, MSD, GSK, Astellas Pharma, Diaceutics, Astra Zeneca and received research grants from Astellas Pharma, QED therapeutics, and macrophage pharma, unrelated to the current work.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: For this type of study formal consent is not required.
